From fibrinogen to fibrin and its dissolution;Du fibrinogène à la fibrine et sa dissolution

Bulletin de l'Academie Nationale de Medecine

Volumn 187, Issue 1, 2003, Pages 69-84

  Juhan Vague, Irène ^a,b   Hans, Michel ^c  

^a TIMONE HOSPITAL   (France)

^b LOUIS PRADEL HOSPITAL   (France)

^c NONE

Author keywords

Arteriosclarosis; Carboxypeptidase U; Fibrin; Fibrinogen; Fibrinolysis; Plasminogen activator inhibitor 1; Risk factors; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 13; FIBRIN; FIBRINOGEN; METALLOPROTEINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ANIMAL; ARTERIOSCLEROSIS; BIOSYNTHESIS; CELL MOTION; COMPARATIVE STUDY; DIABETES MELLITUS; DISEASE MODEL; ENDOTHELIUM CELL; FIBRINOLYSIS; HEMOSTASIS; HUMAN; INSULIN RESISTANCE; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; RISK FACTOR; THROMBOSIS; TRANSGENIC MOUSE; WOUND HEALING;

ANIMALS; ARTERIOSCLEROSIS; CARBOXYPEPTIDASE U; CELL MOVEMENT; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FACTOR XIII; FIBRIN; FIBRINOGEN; FIBRINOLYSIS; HEMOSTASIS; HUMANS; INSULIN RESISTANCE; METALLOPROTEASES; MICE; MICE, TRANSGENIC; PLASMINOGEN ACTIVATOR INHIBITOR 1; RISK FACTORS; THROMBIN; THROMBOSIS; WOUND HEALING;

EID: 0642367290     PISSN: 00014079     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0001-4079(19)34081-6     Document Type: Article

References (41)

1. MOSESSON M.W. - Fibrinogen and fibrin polymerization and functions. Blood Coagul Fibrinolysis, 1999, 10 Suppl 1, S45-8.
2. GREENBERG C.S., BIRCKBICHLER P.J., RICE R.H. - Transglutaminases : multifunctional cross-linking enzymes that stabilize tissues. FASEB J, 1991, 5, 3071-7.
3. SIEBENLIST K.R., MOSESSON M.W. - Progressive cross-linking of fibrin gamma chains increases resistance to fibrinolysis. J Biol Chem, 1994, 269, 28414-9.
4. LIU C.Y., NOSSEL H.L., KAPLAN K.L. - The binding of thrombin by fibrin. J Biol Chem, 1979, 254, 421-5.
5. WEITZ J.I., HUDOBA D., MASSEL J., MARAGANORE J., HIRSH J. - Clot-bound thrombin is protected from inhibition by heparin-antithrombin but is susceptible to inactivation by antithrombin-independent inhibitors. J Clin Invest, 1990, 86, 385-91.
6. COLLEN D., LIJNEN H.R. - Basic and clinical aspects of fibrinolysis and thrombolysis. Blood, 1991, 78, 3114-3124.
7. COLLET J.P., SORIA J., MIRSHAHI M. et al. - Dusart Syndrome : a new concept of the relationship between fibrin clot architecture and fibrin clot degradability : hypofibrinolysis related to an abnormal clot structure. Blood, 1993, 82, 2462-2469.
8. HANSS M., BIOT F. - A Database For Human Fibrinogen Variants. Ann N Y Acad Sci, 2001, 936, 89-90.
9. CARR M.E., ALVING B.M. - Effect of fibrin structure on plasmin-mediated dissolution digestion of plasma clots. Blood Coagul Fibrinolysis, 1995, 6, 567-573.
10. MIRSHAHI M., SORIA J., SORIA C., BERTRAND O., MIRSHAHI M., BASDEVANT A. - Glycosylation of human fibrinogen and fibrin in vitro ; its consequences on the properties of fibrin(ogen). Thromb Res, 1987, 48, 279-289.
11. COLLET J.P., MISHAL Z., LESTY C. et al. - Abnormal fibrin clot architecture in nephrotic patients is related to hypofibrinolysis : influence of plasma biochemical modifications : a possible mechanism for the high thrombotic tendency ? Thromb Haemost, 1999, 82, 1482-9.
12. ERNST E., RESCH K.L. - Fibrinogen as a cardiovascular risk factor : a meta-analysis and review of the literature. Ann Intern Med, 1993, 118, 956-63.
13. ARIENS R.A., LAI T.S., WEISEL J.W., GREENBERG C.S., GRANT P.J. - Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood, 2002, 100, 743-54.
14. HOYLAERTS M., RIJKEN D.C., LIJNEN H.R., COLLEN D. - Kinetics of the Activation of Plasminogen by Human Tissue Plasminogen Activator. Role of Fibrin. J Biol Chem, 1982, 257, 2912-2919.
15. HENDRIKS D., WANG W., SCHARPE S., LOMMAERT M.P., VAN SANDE M. - Purification and characterization of a new arginine carboxypeptidase in human serum. Biochim Biophys Acta, 1990, 1034, 86-92.
16. BAJZAR L., MANUEL R., NESHEIM M.E. - Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J Biol Chem, 1995, 270, 14477-14484.
17. WANG W., BOFFA M.B., BAJZAR L., WALKER J.B., NESHEIM M.E. - A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem, 1998, 273, 27176-21781.
18. BROZE G.J.R., HIGUCHI D.A. - Coagulation Dependent Inhibition of Fibrinolysis : Role of Carboxypeptidase-U and the Premature Lysis of Clots From Hemophilic Plasma. Blood, 1996, 88, 3815-3823.
19. BOUNAMEAUX H., SCHNEIDER P.A., REBER G., DE MOERLOOSE P., KRAHENBUHL. - Measurement of plasma D-Dimer for diagnosis of deep venous thrombosis. Am J Clin Pathol, 1989, 91, 82-85.
20. CHAPMAN H.A., WEI Y. - Protease crosstalk with integrins : the Urokinase Receptor Paradigm. Thromb Haemost, 2001, 86, 124-129.
21. PEPPER M.S. - Extracellular Proteolysis and Angiogenesis. Thromb Haemost, 2001, 86, 346-355.
22. NALBONE G., ALESSI M.C., JUHAN-VAGUE I. - Système fibrinolytique, métalloprotéases et pathologie vasculaire. Médecine/ Sciences, 2001, 17, 170-176.
23. LIJNEN H.R., UGWU F., BINI A., COLLEN D. - Generation of an angiostatin-like fragment from plasminogen by stromelysin 1 (MMP-3). Biochemistry, 1998, 37, 4699-4702.
24. STEFANSSON S., LAWRENCE. - The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature, 1996, 383, 390-391.
25. EREN M., PAINTER C.A., ATKINSON J.B., DECLERCK P.J., VAUGHAN D.E. - Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation, 2002, 106, 491-6.
26. JUHAN-VAGUE I., ALESSI M.C., VAGUE P. - Increased plasma plasminogen activator inhibitor-1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia, 1991, 34, 457-62.
27. SOBEL B.E., WOODCOCK-MITCHELL J., SCHNEIDER D.J, HOLT R.E., MARUTSUKA K., GOLD H. - Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients : a potential factor predisposing to thrombosis and its persistence. Circulation, 1998, 97, 2213-21.
28. JUHAN-VAGUE I., PYKE S.D.M., ALESSI M.C., JESPERSEN J., HAVERKATE F., THOMPSON S.G. - Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation, 1996, 94, 2057-2063.
29. JUHAN-VAGUE I., ALESSI M.C. - Regulation of fibrinolysis in the development of atherothrombosis : role of adipose tissue. Thromb Haemost, 1999, 82, 832-36.
30. ALESSI M.C., PEIRETTI F., MORANGE P., HENRY M., NALBONE G., JUHAN-VAGUE I. - Production of plasminogen activator inhibitor-1 by human adipose tissue : possible link between visceral fat accumulation and vascular disease. Diabetes, 1997, 46, 860-67.
31. BASTELICA D., MORANGE P.E., BERTHET B. et al. - Stromal cells are the main PAI-1 producing cells in human fat. Evidence of differences between visceral and subcutaneous deposits. Arterioscler Thromb Vasc Biol, 2002, 22, 173-178.
32. BASTELICA D., MAVRI A., VERDIER M., BERGOIN M., BERTHET B., JUHAN-VAGUE I., ALESSI M.C. - Relationships between fibrinolytic and inflammatory parameters in human adpose tissue : strong contribution of TNFa receptors to PAI-1 levels. Thromb Haemost, 2002, 88, 481-7.
33. HOTAMISLIGIL G.S., PERALDI P., BUDAVARI A., ELLIS R., WHITE M.F., SPIEGELMAN B.M. - IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance. Science, 1996, 271, 665-8.
34. BRUCKERT E., ANKRI A., GIRAL P., TURPIN G. - Relationship between plasma plasminogen activator inhibitor 1 and hepatic enzyme concentrations in hyperlipidemie patients. Thromb Haemost, 1994, 72, 434-437.
35. MORANGE P.E., LIJNEN H.R., ALESSI M.C., KOPP F., COLLEN D., JUHAN-VAGUE I. - Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. Arterioscler Thromb Vasc Biol, 2000, 20, 1150-1154.
36. LIJNEN H.R., MAQUOI E., MORANGE P. et al. - Nutritionally induced obesity is attenuated in transgenic mice overexpressing plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol., 2003, 23, 78-84.
37. FESTA A., D'AGOSTINO R., TRACY R.P., HAFFNER S.M. - Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes. The Insulin Resistance Atherosclerosis Study. Diabetes, 2002, 51, 1131-1137.
38. VAN TILBURG N.H., ROSENDAAL F.R., BERTINA R.M. - Thrombin activable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood, 2000, 95, 2855-9.
39. SILVEIRA A., SCHATTEMAN K., GOOSSENS F. et al. - Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost, 2000, 84, 364-8.
40. JUHAN-VAGUE I., MORANGE P.E., AUBERT H. et al. - Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler Thromb Vasc Biol, 2002, 22, 867-73.
41. MOSNIER L.O., LISMAN T., VAN DEN BERG H.M., NIEUWENHUIS H.K., MEIJER J.C., BOUMA B.N. - The defective down regulation of fibrinolysis in haemophilia can be restored by increasing the TAFI plasma concentration. Thromb Haemost, 2001, 86, 1035-9.